{"id":"NCT00711009","sponsor":"Abbott","briefTitle":"Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)","officialTitle":"A Randomized, Open-label Study of Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once Daily Versus Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Raltegravir 400 mg Twice Daily in Antiretroviral Naive, HIV-1 Infected Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2009-11","completion":"2010-10","firstPosted":"2008-07-08","resultsPosted":"2011-02-02","lastUpdate":"2012-02-14"},"enrollment":206,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Human Immunodeficiency Virus Infection"],"interventions":[{"type":"DRUG","name":"lopinavir/ritonavir (LPV/r)","otherNames":["ABT-378","lopinavir/ritonavir","LPV/r","Kaletra"]},{"type":"DRUG","name":"emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)","otherNames":["emtricitabine/tenofovir disoproxil fumarate","FTC/TDF","Truvada"]},{"type":"DRUG","name":"raltegravir (RAL)","otherNames":["raltegravir","RAL","Isentress","MK-0518"]}],"arms":[{"label":"LPV/r + FTC/TDF","type":"ACTIVE_COMPARATOR"},{"label":"LPV/r + RAL","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare the safety, tolerability, and antiviral activity of the lopinavir/ritonavir tablet when administered in combination with reverse transcriptase inhibitors to lopinavir/ritonavir tablets when administered in combination with a human immunodeficiency virus type 1 ( HIV-1) integrase inhibitor in antiretroviral naive HIV-1 infected subjects.","primaryOutcome":{"measure":"Percentage of Participants Responding (Plasma HIV-1 Ribonucleic Acid [RNA] Levels Less Than 40 Copies/Milliliter [mL]) at Week 48 Based on the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) Algorithm","timeFrame":"Baseline to Week 48","effectByArm":[{"arm":"LPV/r + FTC/TDF","deltaMin":84.8,"sd":null},{"arm":"LPV/r + RAL","deltaMin":83.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.850"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":37,"countries":["United States","Canada","France","Italy","Poland","Puerto Rico","Spain"]},"refs":{"pmids":["22730929","22180523"],"seeAlso":["http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=Kaletra"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":105},"commonTop":["Diarrhoea","Nausea","Headache","Nasopharyngitis","Hypercholesterolaemia"]}}